Ann: DC2 Signs Multiple Colocation Agreements for Approx. A1.77m, page-14

This stock is now below IPO price and a market cap of just ~$11.4m. And I reckon it's gone way too cheap, if you're long term holder like myself and an opportunity to top up if you have high conviction.

The founder and director Justin Thomas is the largest shareholder with a significant 24% interest in the company (14.3m shares) and he therefore has every incentive to steer this ship in the right direction, to protect his (paper) wealth. I do like the founder led nature of the company. They've also just introduced an employee securities incentive scheme to motivate other employees of the company to do well and build shareholder value.

A new director (Shane Wee) was issued options recently with an exercise price of $0.60, so again every incentive for that new director to kick goals so that those options become in the money within the next four years.

Tier III certification is pending and based on their anticipated timeline, could be received any moment from now up until end of this year. If achieved, I suspect these ridiculously low prices may be a thing of the past. They've also been steadily signing up new clients to add recurring revenue streams.

Hoping this company will end up rewarding the patient long term holder.